

# Wrightington, Wigan and Leigh Teaching Hospitals

NHS Foundation Trust

## Information Governance Department

Suite 9  
Buckingham Row  
Brick Kiln Lane  
Wigan  
WN1 1XX

Email: [foi@wwl.nhs.uk](mailto:foi@wwl.nhs.uk)

Web: [www.wwl.nhs.uk](http://www.wwl.nhs.uk)

Ref: FOI/2024/10018

Date Received: 29<sup>th</sup> July 2024

Response Due: 27<sup>th</sup> August 2024

Date: 2<sup>nd</sup> August 2024

Dear Sir/Madam

With reference to your request for information received on 29<sup>th</sup> July 2024, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

**Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024?**

Name of medicine	Number patients treated
1.1 Benralizumab (Fasenra)	35
1.2 Dupilumab (Dupixent)	65
1.3 Mepolizumab (Nucala)	10
1.4 Omalizumab (Xolair)	31
1.5 Reslizumab (Cinqaero)	0
1.6 Tezepelumab (Tezspire)	<5

**Q2. How many patients were treated for severe asthma, atopic dermatitis, CRwNP and other indications with the following medicines in the 3 months between the start of April 2024 and end of June 2024?**

Name of medicine	Severe asthma (please include all types or references to asthma)	Chronic rhinosinusitis with nasal polyps (CRwNP)	Atopic Dermatitis	Other
2.1 Benralizumab (Fasenra)	35	N/A	N/A	N/A
2.2 Dupilumab (Dupixent)	0	0	43	22
2.3 Mepolizumab (Nucala)	10	0	N/A	0
2.4 Omalizumab (Xolair)	29	0	N/A	<5
2.5 Reslizumab (Cinqaero)	0	N/A	N/A	N/A
2.6 Tezepelumab (Tezspire)	<5	N/A	N/A	N/A

**Q3. How many patients were treated by department in total, regardless of diagnosis, with the following medicines in the 3 months between the start of April 2024 and end of June 2024?**

Name of medicine	Respiratory departments	Dermatology departments	Other
3.1 Benralizumab (Fasenra)	35	0	0
3.2 Dupilumab (Dupixent)	0	65	0
3.3 Mepolizumab (Nucala)	10	0	0
3.4 Omalizumab (Xolair)	29	<5	0
3.5 Reslizumab (Cinqaero)	0	0	0
3.6 Tezepelumab (Tezspire)	<5	0	0

**Q4. How many patients were treated for Asthma the following medicines in the 3 months between the start of April 2024 and end of June 2024?**

*Please answer this question for ICS-LABA combination medicines e.g. Symbicort, Seretide and other branded or generic versions of the combination.*

Name of combination medicine	Pack strength	Number of patients
4.1 Fluticasone with salmeterol	All strengths	41
4.2 Fluticasone with salmeterol	500mcg fluticasone / 50mcg salmeterol	7
4.3 Budesonide with formoterol	All strengths	39

<b>4.4 Budesonide with formoterol</b>	<b>400mcg budesonide / 12mcg formoterol</b>	<5
<b>4.5 Fluticasone with vilanterol</b>	<b>All strengths</b>	9
<b>4.6 Fluticasone with vilanterol</b>	<b>184mcg fluticasone / 22mcg vilanterol</b>	<5
<b>4.7 Beclometasone with formoterol</b>	<b>All strengths</b>	141
<b>4.8 Beclometasone with formoterol</b>	<b>200mcg beclomethasone / 6mcg formoterol</b>	37
<b>4.9 Fluticasone with formoterol</b>	<b>All strengths</b>	<5
<b>4.10 Fluticasone with formoterol</b>	<b>250mcg fluticasone / 10mcg formoterol</b>	<5

The Trust has a policy of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

- a) Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and
- b) Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA).

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,



Gary Masterman  
Deputy Chief Pharmacist

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire, SK9 5AF

Helpline number: 0303 123 111